Clinical Research in Southampton
Southampton Children's Hospital

A A A Text only | Accessibility | Privacy and cookies

Home
About the Trust
Our services
Patients and visitors
Our hospitals
Education
Research
Working here
Contact us

Browse site A to Z

A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

Search results

Go To Advanced Search

Search

You could also try: reply (21), answer (791), reaction (683)

Parvovirus B19 during pregnancy - patient information

Description: This factsheet explains what parvovirus B19 is, the common symptoms and how catching this virus may affect you and your baby
Url: /Media/UHS-website-2019/Patientinformation/Pregnancyandbirth/Parvovirus-B19-during-pregnancy-3648-PIL.pdf

Talimogene laherparepvec (T-VEC)

Description: Chemotherapy Protocol SKIN CANCER Talimogene laherparepvec (T-VEC) Regimen • Skin – Talimogene laherparepvec (T-VEC)
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Skincancer/Talimogene-laherparepvec-T-VEC.pdf

ClofarabineCytarabine

Description: Chemotherapy Protocol ACUTE MYELOID LEUKAEMIA ALL CLOFARABINE-CYTARABINE In-Patient Regimen Clofarabine not licensed in adult patients. This may r
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/AML/ClofarabineCytarabine.pdf

MyelomaMPVBortezomib(SC)MelphalanPrednisolone(35day)Ver1

Description: Chemotherapy Protocol MULTIPLE MYELOMA MPV (SC)-BORTEZOMIB (SC)-MELPHALAN (PO)-PREDNISOLONE (35
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Myeloma/MyelomaMPVBortezomibSCMelphalanPrednisolone35dayVer1.pdf

MyelomaMPVBortezomib(IV)MelphalanPrednisolone(35day)Ver1

Description: Chemotherapy Protocol MULTIPLE MYELOMA MPV (IV)-BORTEZOMIB (IV)-MELPHALAN (PO)-PREDNISOLONE (35 day
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Myeloma/MyelomaMPVBortezomibIVMelphalanPrednisolone35dayVer1.pdf

Lenalidomide

Description: Chemotherapy Protocol MULTIPLE MYELOMA LENALIDOMIDE Regimen • Multiple Myeloma – Lenalidomide Indication • Lenalidomide is recommended,
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Myeloma/Lenalidomide.pdf

Carboplatin(AUC5)-Paclitaxel (21 day)

Description: Chemotherapy Protocol GYNAECOLOGICAL CANCER CARBOPLATIN (AUC5)-PACLITAXEL 21 day Regimen • Ovary-Carboplatin (AUC5)-Paclitaxel (21 day) Indication • First lin
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Ovarian-cancer/CarboplatinAUC5-Paclitaxel21day.pdf

Capecitabine-Oxaliplatin

Description: Chemotherapy Protocol COLORECTAL CANCER CAPECITABINE and OXALIPLATIN (CAPOX) Regimen • Colorectal Cancer – Capecitabine-Oxaliplatin (
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Colorectal/Capecitabine-Oxaliplatin.pdf

Announcement regarding the UHS chief executive Paula Head

Description: Announcement regarding the UHS chief executive Paula Head
Url: /AboutTheTrust/Newsandpublications/Latestnews/2020/November/Announcement-regarding-the-UHS-chief-executive-Paula-Head.aspx

NHS medical director tours COVID testing facilities at UHS

Description: NHS England medical director Professor Stephen Powis met with staff at UHS earlier today (Friday) to find out more about the
Url: /AboutTheTrust/Newsandpublications/Latestnews/2020/October/NHS-medical-director-tours-COVID-testing-facilities-at-UHS.aspx

151 to 160 of 398

Previous … 14 15 16 17 18 … Next